Berbamine overcomes imatinib-induced neutropenia and permits cytogenetic responses in Chinese patients with chronic-phase chronic myeloid leukemia

International Journal of Hematology

Volumn 94, Issue 2, 2011, Pages 156-162

  Zhao, Yanmin ^a   Tan, Yamin ^a   Wu, Gongqiang ^a   Liu, Lizhen ^a   Wang, Yingjia ^a   Luo, Yi ^a   Shi, Jimin ^a   Huang, He ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Berbamine; Chronic myeloid leukemia; Cytogenetic response; Imatinib; Neutropenia

Indexed keywords

BERBAMINE; HYDROXYUREA; IMATINIB; INTERFERON;

ADOLESCENT; ADULT; AGED; ARTICLE; CHINESE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOPOIESIS; HUMAN; MALE; NAUSEA; NEUTROPENIA; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASIAN CONTINENTAL ANCESTRY GROUP; BENZYLISOQUINOLINES; CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; NEUTROPENIA; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052362207     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-011-0887-7     Document Type: Article

References (28)

1. R Hehlmann U Berger M Pfirrmann H Heimpel A Hochhaus J Hasford, et al. 2007 Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia Blood 109 4686 4692 17317858 10.1182/blood-2006-11-055186 1:CAS:528:DC%2BD2sXmt1OgtLg%3D (Pubitemid 46827759)
2. BJ Druker F Guilhot SG O'Brien I Gathmann H Kantarjian N Gattermann, et al. 2006 Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2408 2417 17151364 10.1056/NEJMoa062867 1:CAS:528:DC%2BD28Xht12ntrzM (Pubitemid 44903745)
3. WY Au PB Caguioa C Chuah SC Hsu S Jootar DW Kim, et al. 2009 Chronic myeloid leukemia in Asia Int J Hematol 89 14 23 19101781 10.1007/s12185-008- 0230-0
4. H Kantarjian C Sawyers A Hochhaus F Guilhot C Schiffer C Gambacorti-Passerini, et al. 2002 Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia N Engl J Med 346 645 652 11870241 10.1056/NEJMoa011573 1:CAS:528:DC%2BD38XhsFOjsr8%3D (Pubitemid 34815868)
5. T Nagai J Takeuchi N Dobashi Y Kanakura S Taniguchi K Ezaki, et al. 2008 Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in Japan Int J Hematol 92 111 117 10.1007/s12185-010-0621-x
6. TB Sneed HM Kantarjian M Talpaz S O'Brien MB Rios BN Bekele, et al. 2004 The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase Cancer 100 116 121 14692031 10.1002/cncr.11863 1:CAS:528:DC%2BD2cXkslektw%3D%3D (Pubitemid 37553546)
7. A Quintas-Cardama H Kantarjian S O'Brien G Garcia-Manero MB Rios M Talpaz, et al. 2004 Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia Cancer 100 2592 2597 15197801 10.1002/cncr.20285 1:CAS:528:DC%2BD2cXlsFChs7w%3D (Pubitemid 38715764)
8. D Marin S Marktel N Foot M Bua JM Goldman JF Apperley 2003 Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate Haematologica 88 227 229 12604417 1:CAS:528:DC%2BD3sXotlGhu7w%3D (Pubitemid 37101505)
9. M Germeshausen M Ballmaier K Welte 2007 Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: results of a long-term survey Blood 109 93 99 16985178 10.1182/blood-2006-02-004275 1:CAS:528:DC%2BD2sXivVyrtLg%3D (Pubitemid 46053048)
10. PS Rosenberg BP Alter AA Bolyard MA Bonilla LA Boxer B Cham, et al. 2006 The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy Blood 107 4628 4635 16497969 10.1182/blood-2005-11-4370 1:CAS:528:DC%2BD28XlvFCgsLw%3D (Pubitemid 43882607)
11. K Shimoda S Okamura N Harada W Ikematsu S Kondo C Kawasaki, et al. 1992 Granulocyte colony-stimulating factor receptors on human acute leukemia: biphenotypic leukemic cells possess granulocyte colony-stimulating factor receptors Cancer Res 52 3052 3055 1534271 1:CAS:528:DyaK38XksVWgsrY%3D
12. Y Kumazawa M Kaneko K Inagaki N Matsuzaki K Nomoto 1990 Accelerated recovery from gamma-irradiation-induced leukopenia in mice by the biscoclaurine alkaloid, Cepharanthin-comparison with recombinant human granulocyte colony-stimulating factor Int J Immunopharmacol 12 523 530 1698736 10.1016/0192-0561(90)90116-5 1:CAS:528:DyaK3cXlsVyisL4%3D (Pubitemid 20263598)
13. SY Li W Jei WK Seow YH Thong 1994 Effect of berbamine on blood and bone-marrow stem cells of cyclophosphamide-treated mice Int J Immunopharmacol 16 245 249 8206691 10.1016/0192-0561(94)90019-1 1:CAS:528:DyaK2cXis1SktL8%3D (Pubitemid 24086803)
14. S O'Brien E Berman H Borghaei DJ Deangelo MP Devetten S Devine, et al. 2009 NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia J Natl Compr Canc Netw 7 984 1023 19878641
15. M Baccarani G Saglio J Goldman A Hochhaus B Simonsson F Appelbaum, et al. 2006 Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood 108 1809 1820 16709930 10.1182/blood-2006-02-005686 1:CAS:528: DC%2BD28Xpsl2isrc%3D (Pubitemid 44394987)
16. D Marin S Marktel M Bua RM Szydlo A Franceschino I Nathan, et al. 2003 Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa Leukemia 17 1448 1453 12886230 10.1038/sj.leu.2402996 1:STN:280:DC%2BD3szmvFSgsw%3D%3D (Pubitemid 36986945)
17. Y Zhao L Liu Y Wang G Wu X Lai W Cao, et al. 2009 Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population Int J Hematol 89 445 451 19350352 10.1007/s12185-009-0292-7 1:CAS:528:DC%2BD1MXltFWmur8%3D
18. JM Zaucha E Wyrowinska W Prejzner M Calbecka A Hellmann 2006 Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia Clin Lab Haematol 28 208 210 16706939 10.1111/j.1365-2257.2006.00772.x 1:STN:280: DC%2BD283nslKnug%3D%3D
19. HG Jorgensen M Copland TL Holyoake 2005 Granulocyte colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia Cancer 103 210 211 15540243 10.1002/cncr.20742 (Pubitemid 39665476)
20. D Heim M Ebnother S Meyer-Monard D Tsakiris M Linn A Tichelli, et al. 2003 G-CSF for imatinib-induced neutropenia Leukemia 17 805 807 12682643 10.1038/sj.leu.2402869 1:STN:280:DC%2BD3s7msVyqtw%3D%3D (Pubitemid 36519382)
21. X Liu ZR Zhou 1996 The effect of berbamine on the immunoregulation of BALB/c mice J Chin Med Univ 25 229 231
22. K Yang X Zhao P Xiao G Liu 1982 Clinical trial of berbamine in 405 leukopenia patients Yao Hsueh Tung Pao 17 21 22
23. J Sugita J Tanaka M Kurosawa T Fukuhara S Hashino E Torimoto, et al. 2008 Effects of the mean daily doses of imatinib during the first year on survival of patients with chronic myeloid leukemia in Japan: a study of the Hokkaido Hematology Study Group Eur J Haematol 80 160 163 18028432 1:CAS:528: DC%2BD1cXivFahsbc%3D
24. Y Nannya H Yokota Y Sato G Yamamoto T Asai M Ichikawa, et al. 2008 Molecular and cytogenetic response of chronic myelogenous leukemia treated with imatinib mesylate: one institutional experience in Japan Int J Hematol 88 159 164 18560751 10.1007/s12185-008-0111-6 1:CAS:528:DC%2BD1cXhtlWqs7%2FJ
25. DH Kim L Sriharsha CW Jung S Kamel-Reid JP Radich JH Lipton, et al. 2010 Comprehensive evaluation of time-to-response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: which parameter at which time-point does matter Am J Hematol 85 856 862 20882527 10.1002/ajh.21850 1:CAS:528:DC%2BC3cXhsFWgsbzI
26. DH Kim L Sriharsha W Xu S Kamel-Reid X Liu K Siminovitch, et al. 2009 Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia Clin Cancer Res 15 4750 4758 19584153 10.1158/1078-0432.CCR-09-0145 1:CAS:528:DC%2BD1MXosV2ltbg%3D
27. R Xu Q Dong Y Yu X Zhao X Gan D Wu, et al. 2006 Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity Leuk Res 30 17 23 16023722 10.1016/j.leukres.2005.05.023 1:CAS:528:DC%2BD2MXht1GnsLzE (Pubitemid 41654699)
28. YL Wei L Xu Y Liang XH Xu XY Zhao 2009 Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo Acta Pharmacol Sin 30 451 457 19270722 10.1038/aps.2009.19 1:CAS:528: DC%2BD1MXjvF2htbs%3D